Inhibrx Biosciences, Inc. (NASDAQ:INBX) Stock Has Consensus Target Price of $185.00

Inhibrx Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $185.00.

Several research analysts have recently commented on INBX shares. HC Wainwright lowered their price objective on shares of Inhibrx Biosciences from $245.00 to $220.00 and set a "buy" rating for the company in a research note on Monday, November 16th. Wall Street Zen raised shares of Inhibrx Biosciences from a "strong sell" rating to a "sell" rating in a research note on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. Finally, Citigroup reissued a "market perform" rating on shares of Inhibrx Biosciences in a research report on Friday, September 18th.

Read Our Latest Analysis on INBX

Inhibrx Biosciences Price Performance

INBX stock opened at $68.97 on Friday. Inhibrx Biosciences has a 1 year low of $57.30 and a 1 year high of $155.29. The firm has a market capitalization of $1.02 billion, a PE ratio of -7.61 and a beta of 4.03. The business has a 50 day simple moving average of $91.17 and a 200-day simple moving average of $92.01.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing the consensus estimate of ($2.45) by ($0.01). The firm had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million. On average, equities research analysts expect that Inhibrx Biosciences will post -9.70 EPS for the current year.

Insider Activity

In related news, Director Jon Kayyem bought 5,000 shares of the firm's stock in a transaction that occurred on Wednesday, September 23rd. The stock was purchased at an average cost of $100.00 per share, for a total transaction of $500,000.00. Following the completion of the acquisition, the director owned 434,360 shares in the company, valued at approximately $43,436,000. This trade represents a 1.16% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Mark Lappe bought 10,040 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were bought at an average cost of $84.56 per share, with a total value of $848,982.40. Following the completion of the purchase, the chief executive officer directly owned 745,588 shares in the company, valued at $63,046,921.28. This represents a 1.36% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have purchased 62,540 shares of company stock worth $6,347,507 and have sold 1,500 shares worth $168,590. Insiders own 18.26% of the company's stock.

Institutional Investors Weigh In On Inhibrx Biosciences

Large investors have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its position in Inhibrx Biosciences by 380.3% during the 3rd quarter. Sterling Capital Management LLC now owns 293 shares of the company's stock worth $29,000 after purchasing an additional 232 shares during the period. Integrated Wealth Concepts LLC bought a new position in Inhibrx Biosciences during the 2nd quarter valued at $31,000. Quantbot Technologies LP bought a new stake in Inhibrx Biosciences during the second quarter valued at about $68,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Inhibrx Biosciences during the third quarter worth approximately $75,000. Finally, State of Wyoming bought a new stake in Inhibrx Biosciences in the 2nd quarter valued at $116,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Biosciences Company Profile

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company's oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Read More

Analyst Recommendations for Inhibrx Biosciences (NASDAQ:INBX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inhibrx Biosciences Right Now?

Before you consider Inhibrx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.

While Inhibrx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines